RHONDA MOORE: Open Payments
NPI 1164847562 · WARSAW, KY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$237 in 12 payments from 8 companies in 2025. Trend: 2023 $472 · 2024 $491 · 2025 $237
Food & beverage: $237
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 2 | $44 |
| Novo Nordisk Inc | 2 | $41 |
| GlaxoSmithKline, LLC. | 2 | $39 |
| Lilly USA, LLC | 2 | $38 |
| Verona Pharma, Inc. | 1 | $23 |
| Amgen Inc. | 1 | $21 |
| Esperion Therapeutics, Inc. | 1 | $16 |
| AstraZeneca Pharmaceuticals LP | 1 | $15 |
Products named: VRAYLAR, Ozempic, MOUNJARO, Ohtuvayre, OTEZLA, SHINGRIX, TRELEGY ELLIPTA, NEXLETOL.
Industry payments across KY — which companies pay providers there.
